ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · see citing works

Drug combination studies and their synergy quantification using the Chou-Talalay method

Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · see citing works

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,177 · see citing works

Blinded by the Light: The Growing Complexity of p53

Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

PUMA, a Novel Proapoptotic Gene, Is Induced by p53

Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Spheroid-based drug screen: Considerations and practical approach

Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742 · see citing works

PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells

Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,282 · see citing works

Is a p53-Regulated Inhibitor of G2/M Progression

Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · see citing works

MET signalling: principles and functions in development, organ regeneration and cancer

Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,244 · see citing works

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220 · see citing works

KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene

Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,081 · see citing works

ATM Activation by Oxidative Stress

Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D., & Paull, T. T. (2010) · Science · doi:10.1126/science.1192912 · Cited by 1,079 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · see citing works

Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

Lavin, M. F. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2514 · Cited by 901 · see citing works

Awakening guardian angels: drugging the p53 pathway

Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · see citing works

p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878 · see citing works

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 749 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

Renzo, M. F. D., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., Nordlinger, B., Bretti, S., Bottardi, S., & Giordano, S. (1995) · PubMed · Cited by 456 · see citing works

Targeting Anaplastic Lymphoma Kinase in Lung Cancer

Shaw, A. T., & Solomon, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1591 · Cited by 309 · see citing works

The combined status of ATM and p53 link tumor development with therapeutic responsePreprint

Jiang, H., Reinhardt, H. C., Bártková, J., Tommiska, J., BLOMQVIST, C. P., Nevanlinna, H. A., Bártek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 303 · see citing works

NEMO and RIP1 Control Cell Fate in Response to Extensive DNA Damage via TNF-α Feedforward Signaling

Biton, S., & Ashkenazi, A. (2011) · Cell · doi:10.1016/j.cell.2011.02.023 · Cited by 262 · see citing works

Cooperative effects of genes controlling the G2/M checkpointPreprint

Chan, T. A.-T., Hwang, P. M., Hermeking, H., Kinzler, K. W., & Vogelstein, B. (2000) · Genes & Development · doi:10.1101/gad.14.13.1584 · Cited by 262 · see citing works

Nuclear initiated NF-κB signaling: nemo and ATM take center stage

Miyamoto, S. (2011) · Cell Research · doi:10.1038/cr.2010.179 · Cited by 253 · see citing works

BindingDB Entry 50022503: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

BindingDB (2025) · PubMed · doi:10.7270/q2dv1qm3 · Cited by 235 · see citing works

Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials.

Li, A., Varney, M. L., & Singh, R. K. (2001) · PubMed · Cited by 215 · see citing works

Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas

Olivero, M., Rizzo, M., Madeddu, R., Casadio, C., Pennacchietti, S., Nicotra, M., Prat, M., Maggi, G., Arena, N., Natali, P., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.646 · Cited by 199 · see citing works

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 187 · see citing works

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression

Hwang, C., Matoso, A., Corney, D. C., Flesken‐Nikitin, A., Körner, S., Wang, W., Boccaccio, C., Thorgeirsson, S. S., Comoglio, P. M., Hermeking, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017536108 · Cited by 133 · see citing works

Implications for Therapy

Pandrea, I. V., & LANDAY, A. L. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-387715-4.00003-4 · Cited by 127 · see citing works

Emerging cancer therapeutic opportunities target DNA-repair systems

Ding, J., Miao, Z., Meng, L., & Geng, M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.007 · Cited by 120 · see citing works

The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise

Mandinova, A., & Lee, S. W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001366 · Cited by 113 · see citing works

p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?

Levesque, A. A., & Eastman, A. R. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl214 · Cited by 95 · see citing works

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

Yamazaki, S., Skaptason, J., Romero, D., Lee, J. H., Zou, H. Y., Christensen, J. G., Koup, J. R., Smith, B. J., & Koudriakova, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019711 · Cited by 94 · see citing works

The p53 circuit board

Sullivan, K. D., Gallant‐Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.004 · Cited by 92 · see citing works

Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia

Porter, C. C., Kim, J.-S., Fosmire, S. P., Gearheart, C. M., van Linden, A., Baturin, D., Zaberezhnyy, V., Patel, P. R., Gao, D., Tan, A. C., et al. (2012) · Leukemia · doi:10.1038/leu.2011.392 · Cited by 88 · see citing works

PUMA Promotes Bax Translocation by Both Directly Interacting with Bax and by Competitive Binding to Bcl-XL during UV-induced Apoptosis

Zhang, Y., Xing, D., & Liu, L. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-11-1109 · Cited by 85 · see citing works

Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells

Huang, B., Deo, D. D., Xia, M., & Vassilev, L. T. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0144 · Cited by 72 · see citing works

Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation

París, R., Henry, R. E., Stephens, S. J., McBryde, M., & Espinosa, J. M. (2008) · Cell Cycle · doi:10.4161/cc.6420 · Cited by 63 · see citing works

Signals from the Nucleus: Activation of NF-κB by Cytosolic ATM in the DNA Damage Response

Hadian, K., & Krappmann, D. (2011) · Science Signaling · doi:10.1126/scisignal.2001712 · Cited by 57 · see citing works

A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX

Henry, R. E., Andrysík, Z., París, R., Galbraith, M. D., & Espinosa, J. M. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.498 · Cited by 38 · see citing works

CD40 stimulation sensitizes CLL cells to rituximab-induced cell death

Jak, M., van Bochove, G. G. W., van Lier, R. A. W., Eldering, E., & van Oers, M. H. J. (2011) · Leukemia · doi:10.1038/leu.2011.39 · Cited by 32 · see citing works

BiNGS!SL-seq: A Bioinformatics Pipeline for the Analysis and Interpretation of Deep Sequencing Genome-Wide Synthetic Lethal Screen

Kim, J., & Tan, A. C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-400-1_26 · Cited by 30 · see citing works

The role of gastrin in colorectal carcinogenesis

Takhar, A. S., Eremin, O., & Watson, S. A. (2004) · The Surgeon · doi:10.1016/s1479-666x(04)80093-3 · Cited by 25 · see citing works

Frequent allelic imbalance at the ATM locus in DNA multiploid colorectal carcinomas

Sugai, T., Habano, W., Uesugi, N., Jiao, Y., Nakamura, S.-I., Yoshida, T., & Higuchi, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204731 · Cited by 22 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression

Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · see citing works

P53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Understanding the complexity of p53 in a new era of tumor suppression

Liu, Y., Su, Z., Tavana, O., & Gu, W. J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 519 · see citing works

p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity

Adriaens, C., Standaert, L., Barra, J., Latil, M., Verfaillie, A., Kalev, P., Boeckx, B., Wijnhoven, P. W. G., Radaelli, E., Vermi, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4135 · Cited by 468 · see citing works

Trisomy 21 consistently activates the interferon response

Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., et al. (2016) · eLife · doi:10.7554/elife.16220 · Cited by 362 · see citing works

Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases

Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288 · see citing works

Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics

Goodspeed, A. E., Heiser, L. M., Gray, J. W., & Costello, J. C. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 271 · see citing works

The kinome 'at large' in cancer

Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.18 · Cited by 261 · see citing works

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245 · see citing works

Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

Allen, M. A., Andrysík, Z., Dengler, V. L., Mellert, H. S., Guarnieri, A. L., Freeman, J. A., Sullivan, K. D., Galbraith, M. D., Luo, X., Kraus, W. L., et al. (2014) · eLife · doi:10.7554/elife.02200 · Cited by 238 · see citing works

Stapled Peptides with Improved Potency and Specificity That Activate p53

Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 206 · see citing works

ATM signalling and cancer

Cremona, C. A., & Behrens, A. (2013) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 206 · see citing works

Novel therapeutic targets on the horizon for lung cancer

Tan, W.-L., Jain, A., Takano, A. M., Newell, E. W., Iyer, N. G., Lim, W., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 184 · see citing works

Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activityPreprint

Andrysík, Z., Galbraith, M. D., Guarnieri, A. L., Zaccara, S., Sullivan, K. D., Pandey, A., MacBeth, M. L., Inga, A., & Espinosa, J. M. (2017) · Genome Research · doi:10.1101/gr.220533.117 · Cited by 154 · see citing works

Inhibition of p53 inhibitors: progress, challenges and perspectives

Sanz, G., Singh, M., Peuget, S., & Selivanova, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz075 · Cited by 137 · see citing works

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

Tu, M. M., Lee, F. Y., Jones, R. T., Kimball, A. K., Saravia, E., Graziano, R. F., Coleman, B. M., Menard, K., Yan, J., Michaud, E., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav2437 · Cited by 129 · see citing works

edgeR: a versatile tool for the analysis of shRNA-seq and CRISPR-Cas9 genetic screens

Dai, Z., Sheridan, J. M., Gearing, L. J., Moore, D., Su, S., Wormald, S., Wilcox, S., O’Connor, L., Dickins, R. A., Blewitt, M. E., et al. (2014) · F1000Research · doi:10.12688/f1000research.3928.2 · Cited by 117 · see citing works

Identification of potential synthetic lethal genes to p53 using a computational biology approach

Wang, X., & Simon, R. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-30 · Cited by 91 · see citing works

CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations

Guernet, A. A., Mungamuri, S. K., Cartier, D., Sachidanandam, R., Jayaprakash, A. D., Adriouch, S., Vézain, M., Charbonnier, F., Rohkin, G., Coutant, S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.017 · Cited by 79 · see citing works

A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response

Audetat, K. A., Galbraith, M. D., Odell, A. T., Lee, T., Pandey, A., Espinosa, J. M., Dowell, R. D., & Taatjes, D. J. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00626-16 · Cited by 75 · see citing works

Regulation of the MET oncogene: molecular mechanisms

Zhang, J. Y., & Babic, A. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw015 · Cited by 75 · see citing works

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors

Kalan, S., Amat, R., Schachter, M. M., Kwiatkowski, N. P., Abraham, B. J., Liang, Y., Zhang, T., Olson, C. M., Larochelle, S., Young, R. A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.056 · Cited by 74 · see citing works

Tumor protein D52 (TPD52) and cancer—oncogene understudy or understudied oncogene?

Byrne, J. A., Frost, S., Chen, Y., & Bright, R. K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2006-x · Cited by 71 · see citing works

Development of Synthetic Lethality Anticancer Therapeutics

Fang, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500415t · Cited by 71 · see citing works

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 71 · see citing works

Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis

Li, H., Zhang, Y., Ströse, A., Tedesco, D., Gurova, K. V., & Selivanova, G. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.69 · Cited by 65 · see citing works

Wild type p53 reactivation: From lab bench to clinic

Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 65 · see citing works

A Genetic Screen Identifies TCF3/E2A and TRIAP1 as Pathway-Specific Regulators of the Cellular Response to p53 Activation

Andrysík, Z., Kim, J., Tan, A. C., & Espinosa, J. M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.014 · Cited by 65 · see citing works

shRNA-seq data analysis with edgeR

Dai, Z., Sheridan, J. M., Gearing, L. J., Moore, D., Su, S., Dickins, R. A., Blewitt, M. E., & Ritchie, M. E. (2014) · F1000Research · doi:10.12688/f1000research.3928.1 · Cited by 66 · see citing works

Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer

Spreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3140 · Cited by 64 · see citing works

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner

Esfandiari, A., Hawthorne, T. A., Nakjang, S., & Lunec, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0651 · Cited by 46 · see citing works

The impact of post-transcriptional regulation in the p53 network

Freeman, J. A., & Espinosa, J. M. (2012) · Briefings in Functional Genomics · doi:10.1093/bfgp/els058 · Cited by 44 · see citing works

A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines

Singleton, K. R., Kim, J., Hinz, T. K., Marek, L. A., Casás‐Selves, M., Hatheway, C. M., Tan, A. C., DeGregori, J. V., & Heasley, L. E. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084111 · Cited by 42 · see citing works

Understanding resistance to targeted cancer drugs through loss of function genetic screens

Berns, K., & Bernards, R. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.002 · Cited by 41 · see citing works

MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure

Boccaccio, C., & Comoglio, P. M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.008 · Cited by 41 · see citing works

Synthetic Lethal Vulnerabilities of Cancer

de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 39 · see citing works

ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels

Sullivan, K. D., Palaniappan, V. V., & Espinosa, J. M. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973330 · Cited by 39 · see citing works

ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299.

Li, K., Zhu, Z., Liu, Y.-J., Liu, J., Wang, H., Xiong, Z., Shen, X., Hu, Z., & Zheng, J. (2013) · Europe PMC (PubMed Central) · Cited by 35 · see citing works

Synthetic lethality: a step forward for personalized medicine in cancer

Jariyal, H., Weinberg, F. D., Achreja, A., Nagarath, D., & Srivastava, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.014 · Cited by 30 · see citing works

K-Map: connecting kinases with therapeutics for drug repurposing and development

Kim, J., Yoo, M., Kang, J., & Tan, A. C. (2013) · Human Genomics · doi:10.1186/1479-7364-7-20 · Cited by 31 · see citing works

PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response

Andrysík, Z., Sullivan, K. D., Kieft, J. S., & Espinosa, J. M. (2022) · Nature Communications · doi:10.1038/s41467-022-35089-5 · Cited by 31 · see citing works

Transcriptional Silencing of ALDH2 Confers a Dependency on Fanconi Anemia Proteins in Acute Myeloid Leukemia

Yang, Z., Wu, X., Wei, Y., Polyanskaya, S. A., Iyer, S. V., Jung, M., Lach, F. P., Adelman, E. R., Klingbeil, O., Milazzo, J. P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1542 · Cited by 29 · see citing works

Identification of synthetic lethal pairs in biological systems through network information centrality

Kranthi, T., Rao, S. B., & Manimaran, P. (2013) · Molecular BioSystems · doi:10.1039/c3mb25589a · Cited by 29 · see citing works

Cancer TARGETases: DSB repair as a pharmacological target

Samadder, P., Aithal, R., Beláň, O., & Krejčí, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.007 · Cited by 29 · see citing works

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy

Kim, J., Vasu, V. T., Mishra, R., Singleton, K. R., Yoo, M., Leach, S. M., Farias‐Hesson, E., Mason, R. J., Kang, J., Ramamoorthy, P., et al. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu323 · Cited by 25 · see citing works

Identification of universal and cell-type specific p53 DNA binding

Hafner, A., Kublo, L., Tsabar, M., Lahav, G., & Stewart-Ornstein, J. (2020) · BMC Molecular and Cell Biology · doi:10.1186/s12860-020-00251-8 · Cited by 26 · see citing works

Tetraploidization or autophagy: The ultimate fate of senescent human endometrial stem cells under ATM or p53 inhibition

Borodkina, A. V., Shatrova, A. N., Deryabin, P. I., Grukova, A. A., Nikolsky, N. N., & Burova, E. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1121326 · Cited by 23 · see citing works

SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress

Zipin‐Roitman, A., Aqaqe, N., Yassin, M., Biechonski, S., Amer, M., van Delft, M. F., Gan, O. I., McDermott, S., Buzina, A., Ketela, T. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15147 · Cited by 18 · see citing works

Role of mTOR As an Essential Kinase in SCLC

Kern, J. A., Kim, J., Foster, D. G., Mishra, R., Gardner, E. E., Poirier, J. T., Rivard, C. J., Yu, H., Finigan, J. H., Dowlati, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.026 · Cited by 20 · see citing works

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway

Ludwig, M. P., Galbraith, M. D., Eduthan, N. P., Hill, A. A., Clay, M. R., Tellez, C. M., Wilky, B. A., ELIAS, A. D., Espinosa, J. M., & Sullivan, K. D. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3173 · Cited by 18 · see citing works

Harnessing p53 for targeted cancer therapy: new advances and future directions

Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 18 · see citing works

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

Dimberg, L. Y., Towers, C. G., Behbakht, K., Hotz, T. J., Kim, J., Fosmire, S. P., Porter, C. C., Tan, A. C., Thorburn, A. M., & Ford, H. L. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0234 · Cited by 16 · see citing works

A prolonged exposure of human lung carcinoma epithelial cells to benzo[a]pyrene induces p21-dependent epithelial-to-mesenchymal transition (EMT)-like phenotype

Hýžďalová, M., Procházková, J., Strapáčová, S., Svržková, L., Vacek, O., Fedr, R., Andrysík, Z., Hrubá, E., Líbalová, H., Kléma, J., et al. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.128126 · Cited by 16 · see citing works

Integrated High Throughput Analysis Identifies GSK3 as a Crucial Determinant of p53-Mediated Apoptosis in Lung Cancer Cells

Zhang, Y., Zhu, C., Sun, B., Lv, J., Liu, Z., Liu, S., & Li, H. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478873 · Cited by 13 · see citing works

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway

Wang, Z., Mačáková, M., Bugai, A., Kuznetsov, S. G., Hassinen, A., Lenasi, T., Potdar, S., Friedel, C. C., & Barborič, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad001 · Cited by 11 · see citing works

Computational methods and opportunities for phosphorylation network medicine.

Chen, Y. A., & Eschrich, S. A. (2014) · PubMed · Cited by 10 · see citing works

Human ACAP2 is a homolog ofC. elegansCNT-1 that promotes apoptosis in cancer cells

Sullivan, K. D., Nakagawa, A., Xue, D., & Espinosa, J. M. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1026518 · Cited by 10 · see citing works

Models incorporating chromatin modification data identify functionally important p53 binding sites

Lim, J., Iggo, R. D., & Barker, D. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt260 · Cited by 5 · see citing works

An endothelial cell competition assay for determinants of the response to targeted anti-angiogenics

Halford, M. M., He, M. Y., Amin, N., Paquet‐Fifield, S., Achen, M. G., Vincan, E., & Stacker, S. A. (2025) · Growth Factors · doi:10.1080/08977194.2025.2516463 · Cited by 1 · see citing works

The Human Trisome Project

Espinosa, J. M., Galbraith, M. D., Rachubinski, A. L., & Sullivan, K. D. (2025) · INCLUDE Data Hub · doi:10.71738/p0a9-2v09 · Cited by 1 · see citing works

Laboratory discoveries in uveal melanoma

Jochemsen, A. G., & Jager, M. J. (2014) · doi:10.2217/fmeb2013.13.47

Supplementary Methods from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer

Spreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., et al. (2023) · doi:10.1158/1078-0432.22446339.v1

Supplementary Methods from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer

Spreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., et al. (2023) · doi:10.1158/1078-0432.22446339

Supplementary Table S1 from Transcriptional Silencing of ALDH2 Confers a Dependency on Fanconi Anemia Proteins in Acute Myeloid Leukemia

Yang, Z., Wu, X., Wei, Y., Polyanskaya, S. A., Iyer, S. V., Jung, M., Lach, F. P., Adelman, E. R., Klingbeil, O., Milazzo, J. P., et al. (2023) · doi:10.1158/2159-8290.22540091

LRR1 Acts as an Oncogenic Driver: Synthetic Lethality with PARP Inhibition in Triple-Negative Breast CancerPreprint

Wang, L., Chen, X., Chen, L., & Li, P. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4971486

BindingDB Entry 50045098: Development of synthetic lethality anticancer therapeutics.

BindingDB (2016) · UC San Diego · doi:10.7270/q2vd714c

ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels

Sullivan, K. D., Palaniappan, V. V., & Espinosa, J. M. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973330 · Cited by 39 · see citing works

Ataxia telangiectasia mutated (ATM); c-Met proto-oncogene (MET; HGFR); p53

(2012) · Science-Business eXchange · doi:10.1038/scibx.2012.649

Abstract PR05: Construction of synthetic lethal networks for p53 tumor suppressor pathways identifies candidate therapeutic targets for metastatic, chemotherapy resistant HNSCC

Moser, R. D., Xu, C., Kao, M. C., Jang, I. S., Gurley, K. E., Margolin, A., Grandori, C., Mendez, E., & Kemp, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.pms-pr05

Abstract 1311: ATR inhibition sensitizes p53-deficient cancer cells to chemotherapeutic drugs

Sangster‐Guity, N., Conrad, B., & Bunz, F. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-1311

CG. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene 2011; 30

Aziz, M. H., Shen, H., & Maki, C. G. (2016)